Astrazeneca

FromAstraZeneca ([email protected])
Sent withMailchimp
Subject (133)Imfinzi approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers
Preheader (133)Imfinzi approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers
Typography
Arial
Colors
Text Analysis
Body Words135
Subject Words19
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px752 px
X-Spam Score-0.2
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeEvening

Imfinzi approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers

Imfinzi approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers
Imfinzi approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers